MicuRx(SH:688373) Jing Ji Guan Cha Wang·2026-02-27 08:23Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. is projected to incur a loss of 240 million yuan in 2025, with only one product, Kangtaizuoan tablets, commercialized since its IPO in August 2022, and has yet to achieve annual profitability [1][2] Financial Performance - In 2025, the company reported total revenue of 141.77 million yuan, an increase of 8.83% year-on-year; however, it recorded a net loss attributable to shareholders of 241.61 million yuan and a net loss of 250.27 million yuan after excluding non-recurring gains and losses [1] - Revenue for the years 2022 to 2024 was 48.21 million yuan, 90.78 million yuan, and 130 million yuan respectively, with net losses of 220 million yuan, 420 million yuan, and 440 million yuan [2] Product Development and Market Strategy - The company has only one product, Kangtaizuoan, in the commercialization stage, while other products remain in preclinical or clinical research phases [2] - In September 2025, the company initiated a capital operation plan to issue shares to Nanjing Haiqing Pharmaceutical Co., Ltd. for 1.032 billion yuan, which would result in a change of control, with Haiqing holding 20% of the shares [3] - A strategic cooperation agreement was signed with Haiqing to leverage existing market resources for deeper commercialization of products, with sales revenue targets set for 2026-2028 at 260 million yuan, 388 million yuan, and 600 million yuan respectively [3] Challenges and Future Plans - The planned capital operation was halted in November 2025 due to disagreements with major shareholder Genie Pharma, leading the company to explore alternative financing channels [4] - Concerns regarding liquidity have arisen, prompting inquiries from investors about the company's cash flow and future financing plans [4] - The company reported a significant reduction in expense ratios in Q3 2025, with R&D expense ratio down by 59.84 percentage points and sales expense ratio down by 26.34 percentage points, attributed to strict cost control measures [5]